For decades, skincare sold women a story, packaged in jar promising results. Adverts emphasised the elixir of eternal youth. For decades the business model for skin care relied on packaging and expensive price points as a proxy for efficacy. A 2026 McKinsey report projects the global beauty market will grow 5% annually to reach $590 billion by 2030. But there is a notable shift in behaviour and decision-making. The change emerges in how decisions are made and how that drives purchasing decisions. A further McKinsey x Business of Fashion report found that a quarter of global consumers now base purchasing decisions on scientifically tested and clinically proven results. This figure increases significantly in certain markets, in South Korea jumping to 35%. Women recognise skincare isn’t just about lathering cream on their face, they are auditing the ingredients using data and research. SouthKorea is leading the way in skincare trends and market projected to reach $252.4 billion by 2033 . Within this scrutiny emerges a category that barely existed five years ago: biotech skincare, where longevity science, usually confined to academic journals and animal labs, is asked to survive contact with a bathroom shelf.

The Science: What Epigenetics Actually Means for Skin

Epigenetics is the study of how gene activity changes without altering the underlying DNA sequence itself essentially, which genes get switched on or off, and how strongly, in response to age, environment, and lifestyle. Over the last decade, researchers have built epigenetic clocks: tools that measure biological age rather than the number on a birth certificate, by tracking chemical modifications across the genome. The person most closely associated with this methodology is Steve Horvath, the UCLA geneticist who invented it, and whose independent verification now functions as a kind of gold standard for companies making biological-age claims.

This is the terrain Yuvan Research Inc, a five-year-old biotech startup, has chosen to compete on. In 2023, a peer-reviewed study published in GeroScience found that a treatment developed by the company reversed epigenetic aging in rat tissue by an average of 67.4% across four organs, measured against six independently developed clocks with liver improving 74.6%, blood 64.3%, and heart 46.5%. The treatment involved E5, a plasma fraction derived from young pigs, and the fact that it was verified against multiple independent clocks, rather than one proprietary measure the company controls, is precisely the kind of methodological detail that separates a real longevity claim from a marketing one.

From the Lab to the Face: NEEL Gel and GHK-Cu

What does rat-tissue epigenetics have to do with the cream on your bathroom shelf? Yuvan Research’s consumer product, NEEL Gel , is built around a different compound: GHK-Cu, a naturally occurring copper-binding tripeptide that declines with age and has been studied for tissue regeneration and wound healing for roughly fifty years. Its epigenetic profile is what makes it interesting to a longevity company rather than a conventional cosmetics lab. In a 2014 peer-reviewed paper published in BioMed Research International , researcher Anna Pickart used data from the Broad Institute’s Connectivity Map, a public gene-expression database run jointly by MIT and Harvard Universities to show that GHK-Cu altered expression by 50% or more in roughly a third of the human genes analyzed, shifting them toward patterns associated with younger, healthier tissue. A separate, earlier Broad Institute analysis found that GHK reversed 70% of a 54-gene signature associated with early-stage, metastasis-prone colon cancer, a finding well outside skincare's usual frame of reference, and a reminder that the same molecule can matter to oncology and to a woman's morning routine.

Michael Snyder, Stanford’s Professor of Genetics , former chair of department of genetics and director of its Center for Genomics and Personalized Medicine, has used NEEL Gel for two years. He describes a fast, visible reduction in the fine lines that had been forming over the previous several years. Testimonial evidence from a geneticist is compelling, but it isn’t a trial. The more rigorous evidence sits in NEEL Gel’s own clinical data: an IRB-approved trial, meaning an independent ethics board reviewed the human testing before the product reached market, a step most skincare brands skip entirely, measured a documented increase in collagen fibers via ultrasound imaging in a cohort of 21 middle-aged women under the guidance of Professor Dr. Wayne Carey, a distinguished figure in Dermatology at the Royal Victoria Hospital, McGill University has noted that collagen makes up 60 - 70% of skin structure, and that the overwhelming majority of skincare products on shelves today carry no IRB-approved clinical confirmation of any kind.

The Real Disruption Isn't the Peptide. It's the Standard.

What Yuvan Research is ultimately betting on isn’t a novel ingredient, GHK-Cu is decades old, and copper peptides are already a familiar category on ingredient lists. The bet is on a new evidentiary bar: that skincare should be held to something closer to pharmaceutical proof standards, and that the women driving purchasing decisions in a $590 billion sector are ready to reward the companies willing to meet it, and to walk away from the ones that won't.

That's a structural head start that's hard to retrofit. A brand that has spent a decade building on packaging and influencer partnerships cannot simply bolt on a peer-reviewed study when consumer sentiment shifts; the science has to have been there from the start, and the trial data has to be able to withstand the same scrutiny a woman would apply to a pharmaceutical label.

Longevity science has spent years proving it can move the needle in labs, rat lifespans, epigenetic clocks, plasma fractions verified against independent methodologies. NEEL Gel tests something considerably harder: whether that science can move the needle for a woman standing in front of her bathroom mirror, deciding what she's willing to put on her face tomorrow morning, and what evidence she needs to see first. If the answer is yes, the brands that win the next phase of beauty's growth won't be the ones with the biggest marketing budgets. They'll be the ones willing to show a skeptical, informed buyer their data, and let her decide.